WillItSurvive
Retail and consumer conglomerates · United States

Altria Group

altria.com ↗

Altria sells Marlboro cigarettes and nicotine pouches, the biggest tobacco company in the US.

Defensible for now
Assessed 20 July 2026 · Evidence as of 20 July 2026
Real protection, with named pressure against it.
On the recordSince 20 July 2026 · Checkable from July 14, 2026 · Every call on the record Checkpoint: Maryland federal court rules on lawsuit challenging FDA's enforcement guidance for unauthorized vapes and pouches
The call

Altria keeps raising prices on a shrinking cigarette business while its smoke-free bets stumble against PMI and regulators.

Altria is a big tobacco company that makes Marlboro cigarettes and owns brands like NJOY (e-cigarettes) and on!PLUS (nicotine pouches). The company is hard to replace because the U.S. government strictly limits which tobacco products can be sold, and Altria has deep relationships with stores that stock its products, plus millions of customers who are addicted to nicotine. However, Altria's plan to switch customers away from cigarettes to newer products like on!PLUS is not working well: the government blocked NJOY from being sold, and a rival company called Philip Morris took over the IQOS heated tobacco brand that Altria used to own. The big question is whether Altria can keep raising prices on its shrinking cigarette business forever, or whether it will eventually run out of customers and money.

Why
01
AI pressure: None apparent. AI has no direct role in nicotine delivery or combustible tobacco demand; no AI product threatens this business today. Could AI do the core job? Unlikely.
02
Bigger players: Philip Morris International. PMI reclaimed IQOS US rights in April 2024 and pushes smoke-free share while Altria's NJOY got barred from the market in March 2025. Could a giant copy it? No, they are blocked.
03
What protects it. FDA's PMTA authorization process blocks new entrants and locks in Marlboro's retail shelf space and pricing power.
What would change this call
Q2 2026 earnings on July 30, 2026 show whether EPS growth continues despite volume decline. tests if pricing power still offsets falling cigarette shipments.
Maryland federal court ruling on July 14, 2026 lawsuit against FDA enforcement guidance. could gut protections shielding Altria's authorized nicotine products from unauthorized competitors.
on!PLUS national rollout market-share data through H2 2026. shows whether Altria's smoke-free bet gains ground or stalls against PMI and BAT.
Key numbers
  • FY2025 net revenue $20.14B, down 1.5% (2025-12-31)
  • Domestic cigarette shipments fell ~10% to 61.75B sticks (2025-12-31)
  • Q1 2026 adjusted EPS $1.32, beat estimates (2026-03-31)
Named risks
  • July 14, 2026 federal lawsuit could force FDA to tighten enforcement guidance on unauthorized nicotine products. Severity: high
  • Structural cigarette volume decline (~10% in FY2025) continues to erode the core combustible business. Severity: high
  • Smoke-free pivot remains unproven after NJOY's US market ban and loss of IQOS rights to PMI. Severity: medium
  • CEO transition following Gifford's departure introduces execution uncertainty during the growth pivot. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Philip Morris Internationalgaining onRegained sole U.S. IQOS marketing rights April 30, 2024; ~$38B net sales in 2025
British American Tobaccogaining onVelo pouch growth flagged as a 2026 re-rating opportunity vs Altria's on! stalling at 8.2% share
Japan Tobacco InternationalcontestingAcquired U.S. cigarette maker Vector Group in October 2024, adding domestic combustible competition
Questions people ask
Is Altria profitable in 2026?
Yes. Altria's Q1 2026 adjusted diluted EPS was $1.32, beating estimates, and full-year 2026 guidance was reaffirmed at $5.56 to $5.72 per share as of July 16, 2026, even as FY2025 net revenue fell 1.49% to $20.14 billion.
Who is Altria Group's biggest competitor?
Philip Morris International, spun off from Altria in 2008, is the main rival, with about $38 billion in 2025 net sales. PMI regained independent U.S. IQOS marketing rights on April 30, 2024, after its licensing deal with Altria expired.
Is Altria losing market share?
Yes in cigarettes. Marlboro's U.S. retail share fell to 40.5%, down 1.2 points, in FY2025, and domestic cigarette shipment volume dropped about 10% to 61.75 billion sticks, per a January 29, 2026 earnings analysis.
Why did Altria's NJOY e-vapor business fail in the US?
NJOY ACE was barred from the U.S. market as of March 31, 2025 due to an ITC exclusion and cease-and-desist order. Altria recorded an $873 million goodwill impairment plus $96 million in related expenses through Q3 2025 and confirmed no 2025 re-entry.
Who owns Altria Group?
Altria trades publicly on the NYSE as MO with no parent company. Top institutional holders are Vanguard Group (about 161 million shares) and BlackRock (about 125 million shares); market capitalization was approximately $123.9 billion as of July 20, 2026.
Timeline
  • 2026-07-20Altria market capitalization approximately $123.9 billion
  • 2026-07-14Public health groups sue FDA over guidance allowing marketing of unauthorized e-cigarettes and pouches
  • 2026-05-21U.S. Smokeless Tobacco Company announces manufacturing footprint modernization plan
  • 2026-04-30William Gifford holds final earnings call as CEO amid leadership transition
  • 2026-04-29Q1 2026 results: revenue $5.4B up 3.2% YoY, adjusted EPS $1.32 beats estimates
  • 2026-03-31on!PLUS nicotine pouch achieves broad national distribution
  • 2025-10-31Share repurchase program expanded from $1B to $2B, extended to Dec 31, 2026
  • 2025-08-21NJOY sues FDA over delayed ruling on flavored disposable vapes
  • 2025-03-31NJOY ACE e-vapor barred from U.S. market by ITC exclusion order
  • 2024-04-30IQOS licensing deal with Philip Morris International expires, PMI markets independently
Revision history
20 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Tyson FoodsDiageoKroger
More in Retail and consumer conglomerates →
Sources